Transformation pathways of cocrystal hydrates when coformer modulates water activity

Journal of Pharmaceutical Sciences

Volumn 99, Issue 9, 2010, Pages 3977-3985

  Jayasankar, Adivaraha ^a,b   Roy, Lilly ^a   Rodríguez Hornedo, Naír ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Eutectic point; Hygroscopicity; Phase diagram; Stability; Transition concentration

Indexed keywords

CITRIC ACID; THEOPHYLLINE; WATER;

AQUEOUS SOLUTION; ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; THERMOSTABILITY; VAPOR; X RAY POWDER DIFFRACTION;

EID: 77956381020     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22245     Document Type: Article

References (51)

1. Good DJ, Rodríguez-Hornedo N. 2009. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des 9:2252-2264.
2. Aakeroy C, Forbes S, Desper J. 2009. Using cocrystals to systematically modulate aqueous solubility and melting behavior of an anticancer drug. J Am Chem Soc 131:17048.
3. Byrn SR, Pfeiffer RR, Stowell JG. 1999. Solid-state chemistry of drugs, 2nd edition. West Lafayette, IN: SSCI, Inc.
4. Bethune SJ, Huang N, Jayasankar A, Rodríguez-Hornedo N. 2009. Understanding and predicting the effect of cocrystal components and pH on cocrystal solubility. Cryst Growth Des 9:3976-3988.
5. Bak A, Gore A, Yanez E, Stanton M, Tufekcic S, Syed R. 2008. The cocrystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid cocrystal characterization and pharmacokinetics. J Pharm Sci 97:3942-3956.
6. Schultheiss N, Newman A. 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 9:2950-2967.
7. McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, Mannion R, O'Donnell E, Park A. 2006. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res 23:1888-1897.
8. Trask AV, Motherwell WDS, Jones W. 2005. Pharmaceutical cocrystallization: Engineering a remedy for caffeine hydration. Cryst Growth Des 5:1013-1021. (Pubitemid 40755572)
9. Rager T, Hilfiker R. 2009. Stability domains of multi-component crystals in ternary phase diagrams. Z Phys Chem 223:793-813.
10. Jayasankar A, Reddy LS, Bethune SJ, Rodríguez-Hornedo N. 2009. The role of cocrystal and solution chemistry on the formation and stability of cocrystals with different stoichiometry. Cryst Growth Des 9:889-897.
11. Trask AV, Motherwell WDS, Jones W. 2006. Physical stability enhancement of theophylline via cocrystallization. Int J Pharm 320:114-123.
12. Karki S, Friščić T, Jones W, Motherwell WDS. 2007. Screening for pharmaceutical cocrystal hydrates via neat and liquidassisted grinding. Mol Pharm 4:347-354.
13. Zhu H, Yuen C, Grant DJW. 1996. Influence of water activity in organic solvent+water mixtures on the nature of the crystallizing drug phase. 1. Theophylline. Int J Pharm 135:151-160. (Pubitemid 26260884)
14. Zhu H, Grant DJW. 1996. Influence of water activity in organic solvent plus water mixtures on the nature of the crystallizing drug phase2. Ampicillin. Int J Pharm 139:33-43. (Pubitemid 26276265)
15. Morris KR. 1999. Structural aspects of hydrates and solvates. In: Britain HG, editor. Polymorphism in pharmaceutical solids, 1st edition. New York: Marcel Dekker, Inc. pp 126-180.
16. Stephenson G, Stowell J, Toma P, Pfeiffer R, Byrn S. 1997. Solid-state investigations of erythromycin A dihydrate: Structure, NMR spectroscopy, and hygroscopicity. J Pharm Sci 86:1239-1244.
17. Salameh AK, Taylor LS. 2006. Physical stability of crystal hydrates and their anhydrates in the presence of excipients. J Pharm Sci 95:446-461.
18. Rodríguez-Hornedo N, Lechuga-Ballesteros D, Hsiu-Jean W. 1992. Phase transition and heterogeneous/epitaxial nucleation of hydrated and anhydrous theophylline crystals. Int J Pharm 85:149-162.
19. Wanchai C, Byrn SR, Narueporn S. 2008. Solid state interconversion between anhydrous norfloxacin and its hydrates. J Pharm Sci 97:473-489.
20. Li Y, Chow PS, Tan RBH, Black SN. 2008. Effect of water activity on the transformation between hydrate and anhydrate of carbamazepine. Org Process Res Dev 12:264-270.
21. Qu H, Louhi-Kultanen M, Kallas J. 2006. Solubility and stability of anhydrate/hydrate in solvent mixtures. Int J Pharm 321:101-107. (Pubitemid 44247419)
22. Ticehurst MD, Storey RA, Watt C. 2002. Application of slurry bridging experiments at controlled water activities to predict the solid-state conversion between anhydrous and hydrated forms using theophylline as a model drug. Int J Pharm 247:1-10.
23. Khankari RK, Grant DJW. 1995. Pharmaceutical hydrates. Thermochim Acta 248:61-79.
24. Childs SL, Rodríguez-Hornedo N, Reddy LS, Jayasankar A, Maheshwari C, McCausland L, Shipplett R, Stahly BC. 2008. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. Cryst Eng Commun 11:856-864.
25. Friscic T, Fabian L, Burley JC, Reid DG, Duer MJ, Jones W. 2008. Exploring the relationship between cocrystal stability and symmetry: Is Wallach's rule applicable to multi-component solids? Chem Commun 14:1644-1646.
26. Chiarella RA, Davey RJ, Peterson ML. 2007. Making cocrystals-The utility of ternary phase diagrams. Cryst Growth Des 7:1223-1226.
27. Rodríguez-Hornedo N, Nehm SJ, Seefeldt KF, Pagán-Torres Y, Falkiewicz CJ. 2006. Reaction crystallization of pharmaceutical molecular complexes. Mol Pharm 3:362-367.
28. Zhang GGZ, Henry RF, Borchardt TB, Lou X. 2007. Efficient cocrystal screening using solution-mediated phase transformation. J Pharm Sci 96:990-995. (Pubitemid 46797470)
29. Fleischman SG, Kuduva SS, McMahon JA, Moulton B, Walsh RDB, Rodríguez-Hornedo N, Zaworotko MJ. 2003. Crystal engineering of the composition of pharmaceutical phases: Multiple- component crystalline solids involving carbamazepine. Cryst Growth Des 3:909-919.
30. Bucar D, Henry R, Lou X, Duerst R, MacGillivray L, Zhang G. 2009. Cocrystals of caffeine and hydroxybenzoic acids composed of multiple supramolecular heterosynthons: screening via solution-mediated phase transformation and structural characterization. Cryst Growth Des 9:1932-1943.
31. Rodríguez-Hornedo N, Nehm SJ, Jayasankar A. 2006. Cocrystals: design, properties and formation mechanisms. In: Swarbrick J, editor. Encyclopedia of pharmaceutical technology, 3rd edition. New York: Informa Health Care. pp 615-635.
32. McMahon JA, Bis JA, Vishweshwar P, Shattock TR, McLaughlin OL, Zaworotko MJ. 2005. Crystal engineering of the composition of pharmaceutical phases. 3. Primary amide supramolecular heterosynthons and their role in the design of pharmaceutical cocrystals. Z Kristallogr 220:340-350.
33. Apelblat A, Dov M, Wisniak J, Zabicky J. 1995. The vapor pressure of water over saturated aqueous solutions of malic, tartaric, and citric acids, at temperature from 288K to 323 K. J Chem Thermodyn 27:35-41.
34. Levien BJ. 1955. A physicochemical study of aqueous citric acid solutions. J Phys Chem 59:640-644.
35. Salameh AK, Mauer LJ, Taylor LS. 2006. Deliquescence lowering in food ingredient mixtures. J Food Sci 71:E10-E16.
36. Gracin S, Rasmuson AC. 2004. Polymorphism and crystallization of p-aminobenzoic acid. Cryst Growth Des 4:1013-1023.
37. Nehm SJ, Rodríguez-Spong B, Rodríguez-Hornedo N. 2006. Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst Growth Des 6:592-600.
38. Bell G, Janssen AEM, Halling PJ. 1997. Water activity fails to predict critical hydration level for enzyme activity in polar organic solvents: Interconversion of water concentrations and activities. Enzyme Microb Technol 20:471-477. (Pubitemid 27204408)
39. O'Brien FEM. 1948. The control of humidity by saturated salt solutions. J Sci Instrum 25:73-76.
40. Apelblat A. 1992. The vapour pressures of water over saturated aqueous solutions of barium chloride, magnesium nitrate, calcium nitrate, potassion carbonate, and zinc sulfate at temperatures from 283K to 313 K. J Chem Thermodyn 24:619-626.
41. Jayasankar A, Good DJ, Rodríguez-Hornedo N. 2007. Mechanisms by which moisture generates cocrystals. Mol Pharm 4:360-372.
42. Good DJ, Rodríguez-Hornedo N. 2010. Cocrystal eutectic constants and prediction of solubility behavior. Cryst Growth Des 10:1028-1032.
43. 2H (citric acid) in concentrated aqueous solutions at temperatures from 298.15K to 318.15 K. J Chem Thermodyn 27:347-353.
44. Maffia MC, Meirelles AJA. 2001. Water activity and pH in aqueous polycarboxylic acid systems. J Chem Eng Data 46:582-587.
45. Peng C, Chow AHL, Chan CK. 2001. Hygroscopic study of glucose, citric acid, and sorbitol using an electrodynamic balance: Comparison with unifac predictions. Aerosol SciTechnol 35:753-758.
46. Salameh AK, Taylor LS. 2006. Deliquescence-induced caking in binary powder blends. Pharm Dev Technol 11:453-464.
47. Otsuka M, Kaneniwa N, Kawakami K, Umezawa O. 1990. Effect of surface characteristics of theophylline anhydrate powder on hygroscopic stability. J Pharm Pharmacol 42:606-610.
48. Clegg S, Seinfeld J. 2006. Thermodynamic models of aqueous solutions containing inorganic electrolytes and dicarboxylic acids at 298.15 K. 1. The acids as nondissociating components. J Phys Chem A 110:5692-5717. (Pubitemid 43798613)
49. Kontny MJ, Conners JJ. 2002. Water sorption of drugs and dosage forms. In: Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology, 2nd edition. New York: Marcel Dekker, Inc. pp 2970-2986.
50. Debnath S, Suryanarayanan R. 2004. Influence of processing-induced phase transformations on the dissolution of theophylline tablets. AAPS PharmSciTech 5:1-11.
51. Peng C, Chan MN, Chan CK. 2001. The hygroscopic properties of dicarboxylic and multifunctional acids: measurements and UNIFAC predictions. Environ Sci Technol 35:4495-4501. (Pubitemid 33070060)